• Favourable safety profile of eftilagimod alpha in combination with pembrolizumab
• Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively
• Disease Control Rate of 66% of patients in each Part A and B (24 patients in total)
Ann: Immutep presents positive TACTI-mel melanoma trial data, page-2
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.025(6.33%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 42.0¢ | 39.5¢ | $890.1K | 2.163M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 127863 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 30850 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |